Hrt, a general practice approach: How to reach the most vulnerable

British Journal of Clinical Practice

Volumn 50, Issue 1, 1996, Pages 38-43

  Coope, Jkm ^a   Coope, J R ^a  

^a Bollington Medical Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; THYROXINE;

BONE DENSITY; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; FAMILIAL HYPERLIPEMIA; FRACTURE; GENERAL PRACTICE; HEALTH PROMOTION; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; LIFESTYLE; LONG TERM CARE; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ESTROGEN REPLACEMENT THERAPY; FAMILY PRACTICE; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS;

EID: 0030061857     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. LaRosa JC. Has HRT come of age? lancet 1995; 345: 76-77.
2. Belebetz PE. Hormonal treatment of postmenopausal women. N En^ l .1 Med 1994: 330(15): 1062-1071.
3. Falkeborn M. Persson I, Adami H-O. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br. J Obstet Gvnaecol 1992: 9M: 821-828.
4. Stampfer MJ. Colditz GA. Willett WC el al. Postmenopausal estrogen therapy and coronary heart disease: ten year follow-up from the nurses' health study. N Engl JMeJ 1991: 325: 756-762.
5. Sullivan JM, van der Zwaag R. Lemp GF et al. Postmenopausal estrogen use and coronary artherosclerosis. Ann Intern Med 1988; 108: 358-363.
6. Naessen T, Persson I. Adami H-O el al. Hormone replacement therapy and risk for first hip fracture. Ann Inlern Med 1990: 113: 95-103.
7. Weiss NS. Ure CL, Ballard JH et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens. N Em> l J Med 1980: 303: 1195-1198.
8. Paganini-Hill A. Ross RK. Gerkins VR et al. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981: 95: 28-31.
9. Christiansen C. Christensen MS. McNair PL et al. Prevention of early postmenopausal bone loss: conducted 2-year study of 315 normal females. Eitr J Clin Invest 1980: 10: 273279.
10. Ettinger B. Genant HK. Cann CE. Long-term oestrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985: 102: 319-324.
11. Quigley MET. Martin PL. Bumir AM, Brooks P. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987; 156: 1516-1523.
12. Bush TL, Miller VT. Effects of pharmacologie agents used during menopause: impact on lipids and lipoproteins. In: Mishell D Jr. Ed. Menopause: physiology and pharmacology. Chicago: Year Book Medical Publishers, 1986; 187-208.
13. Newnham HH. Oestrogens and atherosclerotic vascular disease: lipid factors. In: Burger HG, Ed. Bailliere 's Clinical Endocrinology and Metabolism: the Menopause. London: Bailliere Tindall. 1993; 7: 61-63.
14. Barrett-Connor E, Laskso M. Ischaemic heart disease risk in postmenopausal women: effects of oestrogen use on glucose and insulin levels. Arteriosclerosis 1990; 10: 531-534.
15. Collins P. Shaw J, Jiang C, Moss J. Nitric oxide accounts for dose dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation 1994; 90: 1964-1968.
16. Gangar KE. Reid BA. Crook D et al. Oestrogens and atherosclerotic vascular disease: local vascular factors. In: Bailliere 's Clinical Endocrinolog\and Metabolism: the Mé nopause. London: Bailliere Tindall 1993; 7: 47-59.
17. Goldman L. Tosteson ANA. Uncertainty about postmenopausal estrogen. N Engl J Med 1991; 325 (11): 800-802.
18. Vandenbroucke JP. Postmenopausal oestrogen and cardioprotection. Lancet 1991: 337: 833-834.
19. Coope J. Correspondence. Lancet 1991; 337 (8749).
20. Wilkes HC. Meade TW. Hormone replacement therapy in general practice: a survey of doctors in the MRC's General Practice Research Framework. Br Med J 1991: 302: 1317-1320.
21. Barrett-Connor E. Risks and benefits of replacement estrogen. Ann Rev Med 1992: 43: 239-251.
22. Stott N. Screening for cardiovascular risk in general practice. Br Med J 1994: 308: 285-286.
23. Waller D. Agass M, Mant D et al. Health checks in general practice: another example of inverse care? Br Med J 1990; 300: 1115-1118.
24. Coope J, Roberts D. A clinic for the prevention of osteoporosis in general practice. Br J Gen Pract 1990; 40: 295-299.
25. Spector TD. Sambrook PN. Steroid osteroporosis. BrMedJ 1993; 307: 519-520.
26. Ip M. Lam K. Yam Let al. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994: 105(6): 1640-1641.
27. Gennari C. Differential effect of glucocorticoids on calcium absorption and bone mass. BrJRheumatol 1993: 32(2): 11-14.
28. Report of Advisory Group on Osteoporosis. Department of Health 1994.
29. Packe GE, Douglas JG, McDonald AF. Vertebral bone density in asthmatics taking high dose inhaled beclomethasone diproprionate. Thorax 1992; 47: 414-417.
30. Cummings SR, Black DM. Nevitl MC et al. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341: 72-75.
31. The National Osteoporosis Society and Sheffield Clinical Group 1992. The Sheffield Protocol for the Management of the Menopause and Prevention of Osteoporosis. 2nd edn. 1992.
32. Patterson C. Chambers LW. Preventive health care. Lancet 1995; 345: 1611-1616.
33. Coldilz GA. Hankinson SE. Hunter DJ. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. .V Engl J Med 1995: 332: 1589-1593.
34. Davidson NE. Hormone-replacement therapy: breast versus heart versus bone. N Engt J Med 1995; 332(24): 1638-1639.
35. Rodriguez C. Calle EE. Coales RJ et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Enidemiol 1995: 141: 828-835.
36. Skingle SJ. Crisp AJ. Increased bone density in patients on steroids with etidronate. Lancet 1994; 344: 543-544.
37. Meunier PJ. Is steroid-induced osteoporosis preventable? N Eng .1 Med 1993: 328(24): 1781-1782.
38. Sambrook P. Birmingham RN. Kelly P et al. Prevention of corticosteroid osteoporosis. N EnglJ Med 1993: 328: 1747-1752.
39. Reid IR. Ibbertson HK. Calcium supplements in the prevention of steroid-induced osteoporosis 1.2. Am J Clin Nulr 1986; 44: 287-290.
40. Fraser DR. The Physiological economy of vitamin D. Lancet 1983: April 30: 969-972.
41. Jensen J. Christiansen C. Rø dbro P. Cigarette smoking, serum estrogens. and bone loss during hormone-replacement therapy early after menopause. N EnU Med 1985: 313: 973-975.
42. Eastell R. Management of corticosteroid-induced osteoporosis. J Intern Med 1995: 237: 439-447.
43. Messina OD. Barreira JC. Zanchetta JR et al. Effect of low doses of deflazacort vs. prednisone on bone mineral content in premenopausal rheumatoid arthritis. .J Rheumatol 1992: 19: 1520-1526.
44. Lieberman D. Kopernick G. Porath A et al. Sub-clinical worsening of bronchial asthma during estrogen replacement therapy in asthmatic post-menopausal women. Muturims 1995: 21: 153-157.
45. Anderson DC. Sex-hormone-binding globulin. Clin Educ 1974; 3: 69 96.
46. Franklyn JA. Sheppard MC. Thyroxine replacement treatment and osteoporosis. BrMedJ 1990: 300: 693-694.
47. Ross DS, Neer RM. Ridgway EC et al. Subclinical hyperthyroidismand reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987: 82: 1167 1170.
48. Adlin EV, Mauer AH. Marks AD et al. Bone mineral density in postmenopausal women treated with L-thyroxine. Am J Med 1991: 90: 360-366.
49. King AWC. Lorentz TH. Tam SCF. Thyroxine suppressive therapy decreases bone mineral density in postmenopausal women. Clin Endocrinol 1993; 39: 535-540.
50. Oliver MF. Boyd GS. Effect of bilateral ovariectomy on coronary-artery disease and serum-lipid levels. Lancet 1959; October 31: 690-694.
51. Aitken JM, Hart DM. Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J 1973: 3: 515-518.
52. Siddle N, Sarrel P. Whitehead M. The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fenil Steril 1987; 47(1): 94-99.
53. Edwards L. The National Osteoporosis Society's Hysterectomy Study for GPs. J Brit Men Soc 1995: 1(1): 14-17.
54. Ravn P, Lind C. Nilas L. Lack of influence of simple premenopausal hysterectomy on bone mass and bone metabolism. Am J Obstet Cynecol 1995: 172: 891-895.
55. Barlow DH, Brockle JA, Rees CMP et al. Study of general practice consultations and menopausal symptoms. Br Med J 1991: 302: 274-276.
56. Lerner DJ. Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26 year follow up of the Framingham population. Am Heart J 1986; 111: 383-390.
57. Ettinger B. Hormone replacement therapy and coronary artery disease. Obstet Cyn Clin North Am 1990; 17: 741 -757.
58. Spencer I, Unwin N. Pledger G. Hospital investigation of men and women treated for angina. Br Med J 1995: 310: 1576.
59. Kannel WB. Wolf PA, Garrison RJ (Eds). The Framingham Study: an epidemiologic investigation of cardiovascular disease. Section 35, Survival following initial cardiovascular events: thirty yearfollow up. Washington DC: Government Printing Office, 1988: (NIH Publication No. 88: 2969).
60. Murabito JM, Evans JC, Larson MG. Levy D. Prognosis after the onset of CHD. An investigation of differences in outcome between the sexes according to initial CHD presentation. Circulation 1993; 88: 2548-2555.
61. Austin MA. Plasma triglycerides as a risk factor for CHD: the epidemiologic evidence and beyond. Am J Epidemiol 1990; 129: 249-259.
62. Roberts P-J. Reported satisfaction among women receiving hormone replacement therapy in a dedicated general practice clinic and in a normal consultation. Br JGenPract 1995: 45: 79-81.
63. East Cheshire NHS Trust. Guidelines for the use of hormone replacement therapy 1994.
64. Loughran C. Coope J. Personal communication.
65. Fordham JN, Simpson DS, Pitcher O et al. An open access bone densitometry service: report of first year's operation. Br J Rheumatol 1994; 33(7): 668-673.
66. Report of a WHO Study Group: assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organisation. 1994.
67. Coope J, Marsh J. Can we improve compliance with long-term HRT? Maturitas 1992: 15: 151-158.